Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of population-level pharmacogenetic actionability in Alabama.

Clinical and translational science - 1 Nov 2021

Davis Brittney H, Williams Kelly, Absher Devin, Korf Bruce, Limdi Nita A

Abstract excerpt

The evolution of evidence and availability of Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines have enabled assessment of pharmacogenetic (PGx) actionability and clinical implementation. However, population-level actionability is not well-characterized. We leveraged the Alabama Genomic Health Initiative (AGHI) to evaluate population-level PGx actionability. Participants (>18 years),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alabama
Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetics, Population

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Precision Medicine

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34121327
DOI: 10.1111/cts.13097
PMCID: PMC8604228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of population-level pharmacogenetic actionability in Alabama.PMID 34121327Read ↗

Clinically actionable genetic variation in patients with or at high-risk of cardiovascular diseases from the Montreal Heart Institute.Semantic proximity Read ↗

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy UsersSemantic proximity Read ↗

Frequency of pharmacogenomic variation and medication exposures among All of Us ParticipantsSemantic proximity Read ↗

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.Semantic proximity Read ↗

Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study.Semantic proximity Read ↗

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank populationSemantic proximity Read ↗

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.Semantic proximity Read ↗

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community-Dwelling Older Adults.Semantic proximity Read ↗

Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.Semantic proximity Read ↗

Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure.Semantic proximity Read ↗

Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arraysSemantic proximity Read ↗

Recommendations for pharmacogenetic testing in clinical practice guidelines in the USSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.